FDA Waves Bye to 11 Dormant Drug Files
Published Date: 2/20/2026
Notice
Summary
The FDA is officially pulling the plug on 11 drug approvals because the companies stopped selling these medicines. This change affects Masuu Global Solutions LLC and Breckenridge Pharmaceutical, with the withdrawal taking effect on March 23, 2026. No money penalties here—companies just asked to close these files, but they can apply again if they want.
Analyzed Economic Effects
3 provisions identified: 1 benefits, 1 costs, 1 mixed.
Existing Inventory May Still Be Dispensed
Drug products listed in the withdrawn ANDAs that are in inventory on March 23, 2026 may continue to be dispensed until those inventories are used up or the products reach their expiration dates. After that date, introducing those products into interstate commerce without an approved application would violate federal law.
FDA Withdraws 11 Generic Approvals
The FDA is withdrawing approval of 11 abbreviated new drug applications (ANDAs) as of March 23, 2026. Applicants informed the Agency that the products were no longer marketed and asked FDA to withdraw the approvals, including ANDAs filed by Masuu Global Solutions LLC and others listed in the notice.
Withdrawals Are Without Prejudice; Refiling Allowed
The notice says withdrawal of approval under 21 CFR 314.150(c) is without prejudice to refiling and that the applicants waived their opportunity for a hearing. Companies asked FDA to close these files and may reapply if they choose.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-16959, Frequently Asked Questions-Developing Potential Cellular and Gene Therapy Products; Final Guidance for Industry; Availability
The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance titled "Frequently asked Questions--Developing Potential Cellular and Gene Therapy Products." The guidance document provides industry with answers to frequently asked questions (FAQs) and commonly faced issues that arise during the development of cellular and gene therapy (CGT) products. The FAQs represent common questions directed to the Agency and span multiple disciplines, including regulatory review; chemistry, manufacturing, and controls (CMC); pharmacology/toxicology; clinical; and clinical pharmacology. This guidance announced in this notice finalizes the draft guidance of the same title issued on November 19, 2024.
2026-16939, GNT USA, LLC.; Filing of Color Additive Petition
The Food and Drug Administration (FDA or we) is announcing that we have filed a petition, submitted by GNT USA, LLC., c/o Exponent, Inc., proposing that we amend our color additive regulations to provide for the safe use of safflower (Carthamus tinctorius L.) extract as a color additive in various foods at levels consistent with good manufacturing practices.
2026-16942, Food Additives Permitted in Feed and Drinking Water of Animals; Chromium DL-methionine Chelate
The Food and Drug Administration (FDA, we, or the Agency) is amending the regulations for food additives permitted in feed and drinking water of animals to provide for the safe use of chromium DL- methionine chelate as a nutritional source of chromium in cattle feed. This action is in response to a food additive petition filed by Zinpro Corp.
Previous / Next Documents
Previous: 2026-03410, North Pacific Fishery Management Council; Public Meeting
The North Pacific Fishery Management Council’s Ecosystem Committee is meeting online on March 6, 2026, to talk about climate resilience, fish habitats, and groundfish management. This affects fishermen, environmental groups, and communities relying on Alaska’s fisheries. They’ll review plans tied to the Inflation Reduction Act and prepare for future policy updates—no big costs announced, but important decisions are on the horizon!
Next: 2026-03412, Notice of Senior Executive Service Performance Review Board Appointments
The Department of the Interior just named a new team of leaders to review how top executives perform. These appointments start right away and help make sure the best people get recognized and rewarded. If you’re a senior executive, this means your work will be reviewed by this fresh group, but no changes to pay or timing were announced.